Suppr超能文献

相似文献

1
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
J Natl Cancer Inst. 2010 Feb 24;102(4):271-4. doi: 10.1093/jnci/djp499. Epub 2010 Jan 14.
2
Identification of bona fide esophageal adenocarcinoma cell lines.
J Natl Cancer Inst. 2010 Feb 24;102(4):212-3. doi: 10.1093/jnci/djp526. Epub 2010 Jan 14.
3
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
Dig Dis Sci. 2008 Dec;53(12):3055-64. doi: 10.1007/s10620-008-0294-y. Epub 2008 May 30.
4
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
Dis Esophagus. 2008;21(6):514-21. doi: 10.1111/j.1442-2050.2007.00799.x.
5
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
J Thorac Oncol. 2010 May;5(5):719-20. doi: 10.1097/JTO.0b013e3181d86ebf.
8
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.
Br J Pharmacol. 2010 Aug;160(7):1690-8. doi: 10.1111/j.1476-5381.2010.00838.x.
10
Sorafenib.
Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5.

引用本文的文献

2
Esophageal adenocarcinoma models: a closer look.
Front Mol Biosci. 2024 Nov 12;11:1440670. doi: 10.3389/fmolb.2024.1440670. eCollection 2024.
3
miRNA-221 and miRNA-483-3p Dysregulation in Esophageal Adenocarcinoma.
Cancers (Basel). 2024 Jan 30;16(3):591. doi: 10.3390/cancers16030591.
4
Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.
Nat Commun. 2023 Feb 11;14(1):778. doi: 10.1038/s41467-023-36462-8.
5
Establishment, authenticity, and characterization of cervical cancer cell lines.
Mol Cell Oncol. 2022 Jun 1;9(1):2078628. doi: 10.1080/23723556.2022.2078628. eCollection 2022.
7
Oestrogen Receptor Isoforms May Represent a Therapeutic Target in Oesophageal Adenocarcinoma.
Cancers (Basel). 2022 Apr 8;14(8):1891. doi: 10.3390/cancers14081891.
8
Esophageal Tumor Microenvironment.
Adv Exp Med Biol. 2020;1296:103-116. doi: 10.1007/978-3-030-59038-3_6.

本文引用的文献

1
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
Dis Esophagus. 2008;21(6):514-21. doi: 10.1111/j.1442-2050.2007.00799.x.
2
Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line.
Cancer Biol Ther. 2008 Nov;7(11):1753-5. doi: 10.4161/cbt.7.11.6723. Epub 2008 Nov 4.
4
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
Dig Dis Sci. 2008 Dec;53(12):3055-64. doi: 10.1007/s10620-008-0294-y. Epub 2008 May 30.
5
Cancer statistics, 2008.
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
6
Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7.
Cancer Res. 2007 Sep 1;67(17):7996-8001. doi: 10.1158/0008-5472.CAN-07-2064.
8
MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro.
J Surg Res. 2005 Jul 1;127(1):53-8. doi: 10.1016/j.jss.2005.03.013.
10
Focus on Barrett's esophagus and esophageal adenocarcinoma.
Cancer Cell. 2004 Jul;6(1):11-6. doi: 10.1016/j.ccr.2004.06.021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验